NASDAQ:CORT Corcept Therapeutics (CORT) Stock Price, News & Analysis $116.23 +2.20 (+1.93%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$117.29 +1.06 (+0.91%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Corcept Therapeutics Stock (NASDAQ:CORT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corcept Therapeutics alerts:Sign Up Key Stats Today's Range$113.90▼$117.3250-Day Range$91.12▼$123.5752-Week Range$28.66▼$126.38Volume930,254 shsAverage Volume1.72 million shsMarket Capitalization$12.56 billionP/E Ratio276.74Dividend YieldN/APrice Target$138.17Consensus RatingModerate Buy Company Overview Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing medicines that modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol activity in metabolic, psychiatric, oncologic and other serious medical conditions. Corcept’s principal commercial product is Korlym (mifepristone), a glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery. The company also develops investigational therapies intended to selectively block cortisol’s effects while preserving other functions of the glucocorticoid receptor. Corcept was founded in 1998 and is headquartered in Menlo Park, California. Its commercial focus has historically been the United States, where Korlym is marketed, while its research and development programs address potential applications in several therapeutic areas. Joseph K. Belanoff, a co-founder, has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Corcept Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreCORT MarketRank™: Corcept Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 150th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCorcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCorcept Therapeutics has a consensus price target of $138.17, representing about 18.9% upside from its current price of $116.23.Amount of Analyst CoverageCorcept Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Corcept Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth87.10% Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 87.10% in the coming year, from $1.86 to $3.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 276.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 276.74, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.75.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 18.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corcept Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.91% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Corcept Therapeutics has recently decreased by 0.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.85 News SentimentCorcept Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Corcept Therapeutics this week, compared to 12 articles on an average week.Search InterestOnly 5 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,465,845.00 in company stock.Percentage Held by Insiders20.70% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corcept Therapeutics' insider trading history. Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CORT Stock News HeadlinesCorcept’s Miricorilant Study in MASLD: What the Latest Update Means for InvestorsSeptember 30 at 12:31 PM | tipranks.comCorcept Therapeutics Announces Planned Leadership TransitionSeptember 25, 2026 | marketscreener.comMSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)Corcept Therapeutics Incorporated Announces Management ChangesSeptember 23, 2026 | marketscreener.comMCorcept Therapeutics Announces New Endocrinology Division PresidentSeptember 23, 2026 | tipranks.comCorcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In FocusSeptember 22, 2026 | finance.yahoo.comInsider Selling: Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,106,900.00 in StockSeptember 17, 2026 | insidertrades.comCorcept Therapeutics (NASDAQ:CORT) Insider Sean Maduck Sells 25,000 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines CORT Stock Analysis - Frequently Asked Questions How have CORT shares performed this year? Corcept Therapeutics' stock was trading at $34.80 on January 1st, 2026. Since then, CORT stock has increased by 234.0% and is now trading at $116.23. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Wednesday, July, 29th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.34. The business's quarterly revenue was up 31.7% compared to the same quarter last year. Read the conference call transcript. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/29/2026Today10/02/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CORT's financial health is in the Green zone, according to TradeSmith. CORT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CORT CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees730Year Founded1998Price Target and Rating Average Price Target for Corcept Therapeutics$138.17 High Price Target$165.00 Low Price Target$50.00 Potential Upside/Downside+18.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.42 Trailing P/E Ratio276.74 Forward P/E Ratio62.49 P/E GrowthN/ANet Income$99.65 million Net Margins6.52% Pretax Margin3.17% Return on Equity8.26% Return on Assets6.45% Debt Debt-to-Equity RatioN/A Current Ratio2.86 Quick Ratio2.77 Sales & Book Value Annual Sales$761.41 million Price / Sales16.50 Cash Flow$0.92 per share Price / Cash Flow126.31 Book Value$6.16 per share Price / Book18.87Miscellaneous Outstanding Shares108,100,000Free Float85,722,000Market Cap$12.56 billion OptionableOptionable Beta0.40 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CORT) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
